Table 2.

Neurotransmission-related PET maps included in analyses

Protein	Neurotransmitter	Tracer	Measure	n	Age	Reference
HTR1A	Serotonin	[11C]CUMI-101	BPND	8 (5)	28.4 ± 8.8	Beliveau et al.75
HTR1A	Serotonin	[11C]WAY-100635	BPND	35 (17)	26.3 ± 5.2	Savli et al.76
HTR1B	Serotonin	[11C]AZ10419369	BPND	36 (12)	27.8 ± 6.9	Beliveau et al.75
HTR1B	Serotonin	[11C]P943	BPND	23 (8)	28.7 ± 7.0	Savli et al.76
HTR1B	Serotonin	[11C]P943	BPND	65 (16)	33.7 ± 9.7	Gallezot et al.77
HTR2A	Serotonin	[18F]altanserin	BPND	19 (8)	28.2 ± 5.7	Savli et al.76
HTR2A	Serotonin	[11C]Cimbi-36	BPND	29 (14)	22.6 ± 2.7	Beliveau et al.75
HTR2A	Serotonin	[11C]MDL100907	BPND	3 (1)	35 ± 9	Talbot et al.78
HTR4	Serotonin	[11C]SB207145	BPND	59 (18)	25.9 ± 5.3	Beliveau et al.75
HTR6	Serotonin	[11C]GSK215083	BPND	30 (0)	36.6 ± 9.0	Radhakrishnan et al.79
SLC6A4	Serotonin	[11C]DASB	BPND	100 (71)	25.1 ± 5.8	Beliveau et al.75
SLC6A4	Serotonin	[11C]DASB	BPND	18 (6)	30.5 ± 9.5	Savli et al.76
SLC6A4	Serotonin	[11C]MADAM	BPND	10 (2)	range: 51–67	Fazio et al.80
SLC6A4	Serotonin	[11C]MADAM	BPND	16 (2)	range: 21–67	Dukart et al.20
CNR1	Cannabinoid	[18F]FMPEP-d2	VT	22 (11)	male: 27 ± 6; female: 28 ± 10	Laurikainen et al.81
CNR1	Cannabinoid	[11C]OMAR	VT	77 (28)	30.0 ± 8.9	Normandin et al.82.
DRD1	Dopamine	[11C]SCH23390	BPND	13 (7)	33 ± 13	Kaller et al.83.
DRD2	Dopamine	[11C]FLB457	BPND	55 (29)	32.5 ± 9.7	Hansen et al.14.
DRD2	Dopamine	[11C]FLB457	BPND	6 (2)	39.5 ± 6.8	Sandiego et al.84.
DRD2	Dopamine	[18F]fallypride	BPND	58 (22)	18.5 ± 0.6	Jaworska et al.85.
DRD2	Dopamine	[11C]FLB457	BPND	37 (20)	48.4 ± 16.9	Smith et al.86.
DRD2	Dopamine	[11C]raclopride	BPND	7 (0)	24 ± 2	Alakurtti et al.87.
SLC6A3	Dopamine	[123I]FP-CIT	SUVR	174 (65)	61 ± 11	Dukart et al.88.
SLC6A3	Dopamine	[123I]Ioflupano	SUVR	26 (--)	range 35 ~ 65	García-G et al.89.
SLC6A3	Dopamine	[18F]FE-PE2I	SUVR	10 (0)	28.1 ± 6.9	Sasaki et al.90.
GABRA1	GABA	--	--	26 (0)	26 ± 5	Dukart et al.88.
GABRA1	GABA	[11C]flumazenil	Bmax	16 (9)	26.6 ± 8	Nørgaard et al91.
HRH3	Histamine	[11C]GSK189254	VT	8 (1)	31.7 ± 9.0	Gallezot et al.92.
OPRM1	Opioid	[11C]carfentanil	BPND	204 (72)	32.3 ± 10.8	Kantonen et al.93.
OPRM1	Opioid	[11C]carfentanil	BPND	39 (19)	37.0 ± 4.9	Turtonen et al.94.
SLC6A2	Norepinephrine	[11C]MRB	BPND	77 (27)	33.4 ± 9.2	Ding et al.95.
SLC6A2	Norepinephrine	[11C]MRB	BPND	20 (8)	33.3 ± 10.0	Hesse et al.96.
KIF17	Glutamate	[18F]GE-179	VT	29 (8)	40.9 ± 12.7	Galovic et al.97.
SV2A*	--	[11C]UCB-J	BPND	10 (3)	36 ± 10	Finnema et al.98.
VAT1L	Acetylcholine	[18F]FEOBV	SUVR	5 (4)	68.4 ± 3.4	Hansen et al.14.
VAT1L	Acetylcholine	[18F]FEOBV	SUVR	6 (3)	67.0 ± 11.1	Aghourian et al.99.
VAT1L	Acetylcholine	[18F]FEOBV	SUVR	4 (1)	37 ± 10.2	PI: Lauri Tuominen & Synthia Guimond
VAT1L	Acetylcholine	[18F]FEOBV	SUVR	18 (13)	66.8 ± 6.8	Hansen et al.14.
VAT1L	Acetylcholine	[18F]FEOBV	SUVR	5 (1)	68.3 ± 3.1	Bedard et al.100.
CHRM1	Acetylcholine	[11C]LSN3172176	BPND	24 (11)	40.5 ± 11.7	Naganawa et al.101.
GRM5	Glutamate	[11C]ABP688	BPND	22 (10)	67.9 ± 9.6	PI: Rosa-Neto, P. & Kobayashi, E.
GRM5	Glutamate	[11C]ABP688	BPND	28 (13)	33.1 ± 11.2	DuBois et al.102.
GRM5	Glutamate	[11C]ABP688	BPND	74 (49)	20 ± 3.0	Smart et al.103.
GRM5	Glutamate	[11C]ABP688	BPND	22 (10)	67.9 ± 9.6	Hansen et al.14.
CHRNA4	Acetylcholine	[18F]Flubatine	VT	30 (10)	33.5 ± 10.7	Hillmer et al.104.

The Protein column indicate the protein names in the STRING database. Supplementary Table S1 also includes more extensive methodological details, such as Excitatory/Inhibitory, Ionotropic/Metabotropic, and Source toolkit. Values in parentheses (under n) indicate the number of females.

BP_ND parametric and regional non-displaceable binding potential, B_max density (pmol ml⁻¹) converted from binding potential (5-HT) or distributional volume (GABA) using autoradiography-derived densities, V_T tracer distribution volume, SUVR standardized uptake value ratio.

*The synaptic vesicle glycoprotein 2 A(SV2A) is targeted by PET imaging to quantify synaptic density in human brains⁹⁸.